9/15/2022 8:35:45 AM
BioMarin's Gene Therapy For Adults With Severe Hemophilia A, ROCTAVIAN, Assessed To Provide Cost Savings
9/13/2022 9:47:55 AM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Neutral With $74 Price Target
8/4/2022 1:09:50 PM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) FY23 Rev. Estimate To 2327 M From 2319 M
8/4/2022 1:09:38 PM
Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q4 23 Rev. Estimate To 587.0 M From 585.0 M
8/4/2022 1:09:22 PM
Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q3 23 Rev. Estimate To 583.6 M From 581.7 M
8/4/2022 1:09:06 PM
Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q2 23 Rev. Estimate To 580.3 M From 578.4 M
8/4/2022 1:08:51 PM
Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q1 23 Rev. Estimate To 576.6 M From 574.8 M
8/4/2022 1:08:36 PM
Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) FY22 Rev. Estimate To 2100 M From 2084 M
8/4/2022 1:08:23 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q4 22 Rev. Estimate To 527.3 M From 531.6 M
8/4/2022 1:08:07 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q3 22 Rev. Estimate To 520.5 M From 521.7 M
8/4/2022 1:07:42 PM
Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) FY23 Estimate To 0.54 From 0.42
8/4/2022 1:07:29 PM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) Q4 23 Estimate To 0.08 From 0.05
8/4/2022 1:07:18 PM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) Q3 23 Estimate To 0.13 From 0.10
8/4/2022 1:07:08 PM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) Q2 23 Estimate To 0.15 From 0.12
8/4/2022 1:06:56 PM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) Q1 23 Estimate To 0.18 From 0.15
8/4/2022 1:06:42 PM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) FY22 Estimate To 0.74 From 0.59
8/4/2022 1:06:30 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q4 22 Estimate To -0.08 From -0.07
8/4/2022 1:06:05 PM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Neutral With $70 Price Target
8/3/2022 4:07:41 PM
Biomarin Pharmaceutical Inc. (BMRN) Has Raised Its FY22 Revenue Estimate To $2,060 - $2,160 Mln From $2,050 - $2,150 Mln